Advancing Science. Improving Connections.

Zynerba is an orphan-focused, neuropsychiatric, biopharmaceutical company taking a different and exciting transdermal approach to cannabinoids.

Our People

Focusing on the unmet medical needs of patients with rare disorders and their families

Our Company

Progressing our mission to improve the lives of patients battling certain orphan diseases

Our Pipeline

Pioneering cannabinoid treatments for neuropsychiatric conditions

Latest News

12.05

Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the Annual Meeting of the American College of Neuropsychopharmacology

11.29

Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of Neuropsychopharmacology

11.28

Zynerba Pharmaceuticals Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel™ in the Journal of Neurodevelopmental Disorders

11.15

Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in 22q11.2 Deletion Syndrome